Top Markets
#1 Black Phoenix Black Phoenix +829.97%
#2 pipedog pipedog +41.42%
#3 PondCoin PondCoin +34.34%
#4 Bless Bless +32.22%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.51%
#7 Beam Beam +24.69%
#8 Magma Finance Magma Finance +19.36%
#9 Seeker Seeker +19.26%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rang in aandelen #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Aandeelprijs
$64.97
Laatst gesynchroniseerd: 2024-05-20
Marktkapitalisatie
$1.97B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Categorie

Healthcare
Winst voor Alpine Immune Sciences, Inc. (ALPN)
Winst in Mar 2024 TTM: $-36.73M
Volgens de meest recente financiële verslagen van Alpine Immune Sciences, Inc. bedraagt de huidige winst van het bedrijf $-36.73M. In 2022 behaalde het bedrijf een winst van $-55.43M, een daling ten opzichte van de winst van 2021, die $-50.42M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Alpine Immune Sciences, Inc. van 2012 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-36.73M 14.50%
2023 $-32.08M -42.13%
2022 $-55.43M 9.94%
2021 $-50.42M 80.42%
2020 $-27.95M -33.23%
2019 $-41.85M 13.56%
2018 $-36.85M 361.64%
2017 $-7.98M -74.63%
2016 $-31.46M 37.89%
2015 $-22.82M 51.76%
2014 $-15.04M -7.17%
2013 $-16.20M 69.21%
2012 $-9.57M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -14,460.11%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -5,410.35%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 10,833.48%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 8,303.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH